121 related articles for article (PubMed ID: 35950848)
21. Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan.
Harada K; Yamamoto S; Kato K
Expert Opin Biol Ther; 2022 Nov; 22(11):1333-1338. PubMed ID: 36266954
[TBL] [Abstract][Full Text] [Related]
22. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis.
Zhao Y; Song R; Jia Y; Zhang X; Zhang S; Wu C; Zhang R; Guo Z
Curr Oncol; 2022 Sep; 29(9):6610-6627. PubMed ID: 36135088
[TBL] [Abstract][Full Text] [Related]
24. Real-world outcomes with second-line therapy in advanced esophageal squamous cell carcinoma using SEER-Medicare data.
Danese M; Gricar J; Abraham P
Future Oncol; 2022 Mar; 18(8):927-936. PubMed ID: 35081734
[TBL] [Abstract][Full Text] [Related]
25. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma.
Chen J; Su T; Lin Y; Wang B; Li J; Pan J; Chen C
Clin Transl Oncol; 2018 Mar; 20(3):411-419. PubMed ID: 28779422
[TBL] [Abstract][Full Text] [Related]
26. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
[TBL] [Abstract][Full Text] [Related]
27. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
[TBL] [Abstract][Full Text] [Related]
28. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.
Wang ZQ; Wang DS; Wang FH; Ren C; Tan Q; Li YH
Invest New Drugs; 2021 Apr; 39(2):516-523. PubMed ID: 33070249
[TBL] [Abstract][Full Text] [Related]
29. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of First-line Therapies for Advanced Unresectable Oesophageal Squamous Cell Cancer: a Systematic Review and Network Meta-analysis.
Nian Z; Zhao Q; He Y; Xie R; Liu W; Chen T; Huang S; Dong L; Huang R; Yang L
Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):30-38. PubMed ID: 37827946
[TBL] [Abstract][Full Text] [Related]
31. Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis.
Mohammad NH; ter Veer E; Ngai L; Mali R; van Oijen MG; van Laarhoven HW
Cancer Metastasis Rev; 2015 Sep; 34(3):429-41. PubMed ID: 26267802
[TBL] [Abstract][Full Text] [Related]
32. The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Ter Veer E; Haj Mohammad N; van Valkenhoef G; Ngai LL; Mali RMA; Anderegg MC; van Oijen MGH; van Laarhoven HWM
J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27576566
[TBL] [Abstract][Full Text] [Related]
33. Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.
Randrian V; Adenis A; Desrame J; Barbier E; Di Fiore F; Lièvre A; Dahan L; Laurent-Puig P; Mineur L; Breysacher G; Roquin G; Louafi S; Lopez A; Louvet C; Borg C; Metges JP; Faroux R; Gaba L; Manfredi S; Tougeron D
Dig Liver Dis; 2020 Mar; 52(3):347-350. PubMed ID: 31899122
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma.
Zhao Z; Yin MM; Zhao WF; Wang CJ
Medicine (Baltimore); 2023 Aug; 102(33):e34794. PubMed ID: 37603519
[TBL] [Abstract][Full Text] [Related]
35. A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404).
Nomura M; Kii T; Kawada J; Hirota M; Ohta T; Matsuyama J; Sakai D; Shimokawa T; Kurokawa Y; Kawakami H; Tsujinaka T; Satoh T
Esophagus; 2022 Oct; 19(4):711-716. PubMed ID: 35723843
[TBL] [Abstract][Full Text] [Related]
36. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.
Lu M; Wang X; Shen L; Jia J; Gong J; Li J; Li J; Li Y; Zhang X; Lu Z; Zhou J; Zhang X
Cancer Sci; 2016 Apr; 107(4):486-90. PubMed ID: 26797530
[TBL] [Abstract][Full Text] [Related]
37. SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study.
Mu L; Song Y; Zhao K; Liu Y; Fan Q; Wang X; Li Q; Wang X; Huang J
Thorac Cancer; 2021 May; 12(9):1373-1381. PubMed ID: 33760397
[TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.
Cao Y; Qin S; Luo S; Li Z; Cheng Y; Fan Y; Sun Y; Yin X; Yuan X; Li W; Liu T; Hsu CH; Lin X; Kim SB; Kojima T; Zhang J; Lee SH; Bai Y; Muro K; Doi T; Bai C; Gu K; Pan HM; Bai L; Yang JW; Cui Y; Lu W; Chen J
ESMO Open; 2022 Feb; 7(1):100341. PubMed ID: 34973513
[TBL] [Abstract][Full Text] [Related]
39. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.
Wang ZX; Cui C; Yao J; Zhang Y; Li M; Feng J; Yang S; Fan Y; Shi J; Zhang X; Shen L; Shu Y; Wang C; Dai T; Mao T; Chen L; Guo Z; Liu B; Pan H; Cang S; Jiang Y; Wang J; Ye M; Chen Z; Jiang D; Lin Q; Ren W; Wang J; Wu L; Xu Y; Miao Z; Sun M; Xie C; Liu Y; Wang Q; Zhao L; Li Q; Huang C; Jiang K; Yang K; Li D; Liu Y; Zhu Z; Chen R; Jia L; Li W; Liao W; Liu HX; Ma D; Ma J; Qin Y; Shi Z; Wei Q; Xiao K; Zhang Y; Zhang Y; Chen X; Dai G; He J; Li J; Li G; Liu Y; Liu Z; Yuan X; Zhang J; Fu Z; He Y; Ju F; Liu Z; Tang P; Wang T; Wang W; Zhang J; Luo X; Tang X; May R; Feng H; Yao S; Keegan P; Xu RH; Wang F
Cancer Cell; 2022 Mar; 40(3):277-288.e3. PubMed ID: 35245446
[TBL] [Abstract][Full Text] [Related]
40. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
